Shandong Jincheng Pharmaceutical Group Co., Ltd
300233.SZ · SHZ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.77 | -1.04 | 0.21 | -0.85 |
| FCF Yield | 3.38% | 5.02% | -1.35% | 0.54% |
| EV / EBITDA | 6.68 | 10.31 | 13.62 | 24.33 |
| Quality | ||||
| ROIC | 4.67% | 4.39% | 6.74% | 3.10% |
| Gross Margin | 40.13% | 41.40% | 46.22% | 52.62% |
| Cash Conversion Ratio | 1.43 | 3.44 | 0.89 | 3.55 |
| Growth | ||||
| Revenue 3-Year CAGR | -1.27% | 4.08% | 5.78% | 3.94% |
| Free Cash Flow Growth | -52.06% | 372.09% | -293.38% | -77.70% |
| Safety | ||||
| Net Debt / EBITDA | -0.83 | -1.03 | -0.33 | -0.73 |
| Interest Coverage | 13.64 | 8.62 | 12.67 | 7.63 |
| Efficiency | ||||
| Inventory Turnover | 3.37 | 4.14 | 3.25 | 3.80 |
| Cash Conversion Cycle | 84.46 | 25.15 | 55.22 | 49.12 |